tryptophan benzyl ester | 774485-83-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tryptophan benzyl ester
• 英文别名: NCI202376；Trp-OBzl；benzyl 3-(3-indolyl)-2-aminopropionate；DL-tryptophan benzyl ester；Tryptophan-benzylester；Tryptophane benzyl ester；benzyl 2-amino-3-(1H-indol-3-yl)propanoate
• CAS: 774485-83-5
• 化学式: C₁₈H₁₈N₂O₂
• 分子量: 294.353
• InChiKey: TYQYRKDGHAPZRF-UHFFFAOYSA-N

物化性质

• 沸点：
  489.9±35.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tryptophan benzyl ester 在 吡啶 、 对甲苯磺酸 、 二氯磷酸苯酯 作用下， 以 二氯甲烷 为溶剂， 反应 50.0h， 生成 benzyl 3-(1H-indol-3-yl)-2-isocyanopropanoate
  参考文献：
  名称：

  JP2015/42622

  摘要：

  公开号：
• 作为产物：
  描述：

  DL-色氨酸 、 苯甲醇 在 camphor-10-sulfonic acid 作用下， 反应 72.0h， 以10%的产率得到tryptophan benzyl ester
  参考文献：
  名称：

  JP2015/42622

  摘要：

  公开号：

文献信息

• Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof
  申请人：Nippon Kayaku Kabushiki Kaisha

  公开号：US20200190101A1

  公开（公告）日：2020-06-18

  Provided is a pharmaceutical preparation that is suitable for more effectively exhibiting the efficacy of a glutamic acid derivative, which is a GGT-recognizable prodrug, by producing a composition including a glutamic acid derivative capable of rapidly releasing a physiologically active substance by being recognized by GGT, or a pharmacologically acceptable salt thereof; and a block copolymer in which a polyethylene glycol segment is linked to a polyamino acid segment with a hydrophobic group. Particularly, the composition based on a glutamic acid derivative that uses an antitumor compound as a physiologically active substance is capable of effectively accumulating the glutamic acid derivative at a tumor affected area, exhibits a superior effect against tumors, and is capable of suppressing the release of a physiologically active substance in bone marrow tissue where the expression ratio of GGT is low. Therefore, side effects such as myelosuppression, which pose a problem in the use of antitumor drugs, may be avoided.

  提供的是一种药物制剂，适用于更有效地展现谷氨酸衍生物的功效，该衍生物是一种GGT可识别的前药，通过制备包括一种能够被GGT识别从而快速释放生理活性物质的谷氨酸衍生物或其药理学可接受的盐的组合物；以及一种嵌段共聚物，其中聚乙二醇段与一个疏水基团连接到一个聚氨基酸段。特别是，基于谷氨酸衍生物的组合物使用抗肿瘤化合物作为生理活性物质，能够有效地在受肿瘤影响的区域积累谷氨酸衍生物，对肿瘤具有优越效果，并能够抑制在GGT表达比例较低的骨髓组织中释放生理活性物质。因此，可以避免使用抗肿瘤药物时可能出现的骨髓抑制等副作用。
• Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues
  申请人：Behforouz Mohammad

  公开号：US20060079497A1

  公开（公告）日：2006-04-13

  Lavendamycin analogues, methods for their synthesis, and methods for their use in the treatment of diseases such as cancer and HIV infection are described.

  Lavendamycin类似物，其合成方法，以及在治疗癌症和HIV感染等疾病中使用的方法被描述。
• Novel Lavendamycin Analogues as Potent HIV-Reverse Transcriptase Inhibitors:  Synthesis and Evaluation of Anti-Reverse Transcriptase Activity of Amide and Ester Analogues of Lavendamycin
  作者：Mohammad Behforouz、Wen Cai、Mark G. Stocksdale、Jennifer S. Lucas、Joo Yong Jung、Daniel Briere、Aiqin Wang、Kevin S. Katen、Nancy C. Behforouz

  DOI：10.1021/jm0304414

  日期：2003.12.1

  obtained, respectively, by further transformations of 13-15 and 17. Several lavendamycins were found to be potent HIV reverse transcriptase inhibitors with very low toxicity in vitro and in vivo. Several compounds also acted either additively or synergistically to inhibit enzyme activity together with AZT-triphosphate.

  通过短而有效的方法合成了包括两种水溶性衍生物的新型拉达霉素。7-N-酰基氨基-2-甲酰基喹啉-5,8-二酮与色氨酸的Pictet-Spengler缩合产生拉文达霉素酯或酰胺11-17。通过进一步转化13-15和17，分别获得了Lavendamycins 18-21。发现了几种lavendamycins是有效的HIV逆转录酶抑制剂，在体内和体外均具有极低的毒性。几种化合物还与AZT-三磷酸酯相加或协同作用来抑制酶的活性。
• Viral polymerase inhibitors
  申请人：——

  公开号：US20020065418A1

  公开（公告）日：2002-05-30

  A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3 6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 )alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

  该化合物的结构式为I:1，其中：X为CH或N；Y为O或S；Z为OH、NH2、NMeR3、NHR3、OR3或含有1至4个异原子（0、N和S）的5-或6-成员杂环，该杂环可选择性地与1至4个取代基取代；A为N、COR7或CR5，其中R5为H、卤素或（C1-6）烷基，R7为H或（C1-6）烷基，但X和A不能同时为N；R6为H、卤素、（C1-6）烷基或OR7，其中R7为H或（C1-6）烷基；R1选自包括含有1至4个异原子（O、N和S）的5-或6-成员杂环、苯基、苯基（C1-3）烷基、（C2-6）烯基、苯基（C2-6）烯基、（C3-6）环烷基、（C1-6）烷基、CF3、含有1至4个异原子（O、N和S）的9-或10-成员杂环的群体，其中该杂环、苯基、苯基（C2-6）烯基和苯基（C1-3）烷基、烯基、环烷基、（C1-6）烷基和杂环均可选择性地与1至4个取代基取代；R2选自（C1-6）烷基、（C3-7）环烷基、（C3-7）环烷基（C1-3）烷基、（C6-10）双环烷基、金刚烷基、苯基和吡啶基，所有这些基均可选择性地与1至4个取代基取代；R3选自H、（C1-6）烷基、（C3-6）环烷基、（C3-6）环烷基（C1-6）烷基、（C6-10）芳基、（C6-10）芳基（C1-6）烷基、（C2-6）烯基、（C3-6）环烷基（C2-6）烯基、（C6-10）芳基（C2-6）烯基、N(C1-6)烷基2、NHCOO(C1-6)烷基（C6-10）芳基、NHCO（C6-10）芳基、（C1-6）烷基-含有1至4个异原子（O、N和S）的5-或10-原子杂环和含有1至4个异原子（O、N和S）的5-或10-原子杂环；其中所述烷基、环烷基、芳基、烯基和杂环均可选择性地与1至4个取代基取代；n为零或1；或其可检测衍生物或盐。该发明的化合物可用作乙型肝炎病毒复制的抑制剂。该发明还提供了一种治疗或预防乙型肝炎病毒感染的方法。
• [EN] USE OF ESTER DERIVATIVE OF TRYPTOPHAN AS DEODORANT AND/OR PERFUME AGENT<br/>[FR] UTILISATION D'UN DÉRIVÉ D'ESTER DE TRYPTOPHANE EN TANT QUE DÉSODORISANT ET/OU PARFUM DE TOILETTE
  申请人：OREAL

  公开号：WO2016097398A1

  公开（公告）日：2016-06-23

  This invention relates to the use of at least one following compound having formula (I), as well as the salts thereof, the optical and geometric isomers thereof, and the solvates thereof, as deodorant agent for treating body odor, preferably underarm odor:

  本发明涉及使用至少一种具有以下化合物（I）的公式，以及其盐，光学和几何异构体以及溶剂合物，作为治疗体味，特别是腋下味的除臭剂：